Commercialization: Page 38
-
PharmaVoice Team/PharmaVoice
Advertising to Segments of the Customer Base
For many marketers today, audience segmentation is becoming a key strategic activity when conducting audience analysis. At the most basic level, audience segmentation is the process of dividing a large group of people into homogeneous subgroups — or segments — based upon those who have similar ne...
By Taren Grom • Feb. 1, 2016 -
PharmaVoice Team/PharmaVoice
The Coming Antibiotic Crisis
For the last 70 years, antibiotics have greatly reduced illness and death from infectious diseases. But these drugs have been used so widely and for so long that the infectious organisms the antibiotics are designed to kill have adapted to them, making the drugs less effective. In the past 25 yea...
By Denise Myshko • Feb. 1, 2016 -
PharmaVoice Team/PharmaVoice
Patients and Patient Organizations Power Rare Disease Therapies
For most of the pharmaceutical industry, the focus on patient centricity is a relatively new phenomenon, and the industry continues to shift its focus to include patients as stakeholders when planning its marketing strategies, clinical trials, and R&D strategies. However, for the rare disease...
By Robin Robinson • Feb. 1, 2016 -
PharmaVoice Team/PharmaVoice
Mental Illness: An Underserved Area
Advances in brain science and the understanding of mental health disorders have led to the approval of new medicines, but mental health disorders still take a huge toll on Americans. The National Institute of Mental Health (NIMH) estimates that one in four American adults — 61.5 million people — ...
By Denise Myshko • Feb. 1, 2016 -
PharmaVoice Team/PharmaVoice
Alzheimer's Research Update
Alzheimer’s is at the forefront of brain research; 90% of what we know about Alzheimer’s has been discovered in the last 15 years. But while research has discovered much about this devastating disease, there is still much we don’t know. Alzheimer’s is one of the most complex diseases researchers ...
By Denise Myshko • Feb. 1, 2016 -
PharmaVoice Team/PharmaVoice
Quiet Achiever: Japan Puts Focus On Innovation
A s one of the world’s biggest economies and a well-established pharmaceutical powerhouse, Japan has for many years been a difficult market for foreign companies to enter independently. Increasingly, however, the Japanese market is opening to international companies. “In the past companies were e...
By Kim Ribbink • Feb. 1, 2016 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
The Year Ahead Last month we identified 10 mega-trends that we, as well as others, think will impact the industry going forward. One of these trends is the increasing focus on the brain and the research efforts ongoing to understand the mysteries of this three-pound organ. And while scientists h...
By Taren Grom • Jan. 1, 2016 -
PharmaVoice Team/PharmaVoice
UpFront
Industry at Large Helping Kids with Asthma Medikidz and Meda Pharmaceuticals have launched Explain Asthma, a comic book series launched in conjunction with the American College of Asthma, Allergy, and Immunology (ACAAI). The series is designed to help families gain an accurate understanding of as...
By PharmaVoice Team • Jan. 1, 2016 -
PharmaVoice Team/PharmaVoice
mHealth
Quintiles Contributes Open Source Code to ResearchKit Trending Now: Enhancements enable patient engagement tools for ResearchKit-based apps. Quintiles has contributed enhancements to the ResearchKit framework that provide developers with extensions that support additional capabilities, which, in...
By PharmaVoice Team • Jan. 1, 2016 -
PharmaVoice Team/PharmaVoice
What's New
New Agency Brand Architecture Trending now: Publicis Health Media launches new model across its three U.S. hubs. Publicis Health Media (PHM) has launched a new branding architecture, affecting its three key office locations in Philadelphia, New York, and Chicago. The strategic branding restruct...
By PharmaVoice Team • Jan. 1, 2016 -
PharmaVoice Team/PharmaVoice
Pharma Trax
Adverse Drug Event Reporting in U.S. Plagued by Incompleteness and Inaccuracy Trending now: A high proportion of healthcare professionals have no ADE reporting experience. Voluntary adverse drug event (ADE) reporting in the United States is incomplete, inaccurate, and inefficient, which could den...
By PharmaVoice Team • Jan. 1, 2016 -
PharmaVoice Team/PharmaVoice
Tools of the Trade
PerkinElmer Launches Signals for Translational Trending Now: New cloud-based informatics platform supports complete precision medicine workflow. PerkinElmer has launched PerkinElmer Signals for Translational, a cloud-based data management, aggregation, and analysis platform for pharmaceutical...
By PharmaVoice Team • Jan. 1, 2016 -
PharmaVoice Team/PharmaVoice
The Calendar
Coming Attractions The 7th Annual SCOPE Summit, Feb. 23-25, 2016, Miami, offers three stimulating days of in-depth discussions in 12 different conferences, four pre-conference workshops, and two symposia focused on issues related to each aspect of clinical trial planning and management: data inte...
By PharmaVoice Team • Jan. 1, 2016 -
PharmaVoice Team/PharmaVoice
The Brain: The Decade Ahead
The three-pound organ — made up of more than 100 billion nerves — that serves as the center of the nervous system is one of the most complex parts of the human body. Only recently have researchers and scientists begun to understand the brain and what can go wrong. This special forum kicks off a y...
By Denise Myshko and Robin Robinson • Jan. 1, 2016 -
PharmaVoice Team/PharmaVoice
Sales Reps: A Changing Conversation
There are few sectors that have experienced more upheaval than pharmaceutical sales, with Food & Drug Administration rules, evolving healthcare policies, and the movement of many healthcare practitioners from private, independent offices to group practices all contributing to an increasingly ...
By Taren Grom • Jan. 1, 2016 -
PharmaVoice Team/PharmaVoice
Advertising Agency Hot Topics
In late 2015, the American Medical Association called for a ban on DTC advertising of prescription drugs and medical devices, drawing the conclusion that the billions of advertising dollars being spent to promote prescription products was helping to inflate the cost of prescription drugs. Physici...
By Taren Grom • Jan. 1, 2016 -
PharmaVoice Team/PharmaVoice
Beyond Pricing: What Payers Want
Value-assessment mechanisms, comparative effectiveness, and health economics and outcomes research are among several factors that are forcing the life-sciences industry to better illustrate the overall value of its products in an attempt to retain some power over insurance reimbursement decisions...
By Robin Robinson • Jan. 1, 2016 -
PharmaVoice Team/PharmaVoice
Pharma R&D is Now Biomarker-Driven
Biomarkers are becoming an essential part of the drug discovery and development process. A biomarker-driven approach to developing targeted therapies and patient selection strategies has the potential to increase success in the drug development process, decrease costs, and ultimately improve pati...
By Denise Myshko • Jan. 1, 2016 -
PharmaVoice Team/PharmaVoice
Despite Turbulence, Brazil Remains A Priority Market
A BRIC nation and the largest economy in South America, Brazil is regarded by most industries as a key market. Starting in the mid-1990s the country entered a period of economic stabilization, followed by strong growth in the early 2000s, driven by the commodities sector. In addition, Brazil expe...
By Kim Ribbink • Jan. 1, 2016 -
PharmaVoice Team/PharmaVoice
SHOWCASE FEATURE: Social Anxiety
Of the 50 largest pharmaceutical companies worldwide, according to a study by the IMS Institute for Healthcare Informatics, only half are even dabbling in social media. Furthermore, only 10 of these companies are using the big three — Facebook, Twitter, and YouTube — and an even smaller number ar...
By Taren Grom • Jan. 1, 2016 -
PharmaVoice Team/PharmaVoice
Hey, Pharma! The Social Train Has Left! Get on the Bus!
Pharma! Time to stop waiting for the long-anticipated social media guidance from the FDA and procrastinating on developing a social brand footprint. Social media is now part of the cost of entry in connecting with your customers. Consumers expect — and are accustomed to — brands being present on ...
By Martha Walz • Jan. 1, 2016 -
PharmaVoice Team/PharmaVoice
Becoming Peers With Professionals On Social Networks
The ecosystem of social networks for healthcare professionals is incredibly diverse. For an increasing number of physicians in the United States, there is no epicenter for online dialogue like Facebook, nor a network with the meteoric growth of SnapChat or Instagram. What is happening is a quickl...
By Chris Cullman • Jan. 1, 2016 -
PharmaVoice Team/PharmaVoice
Reaching Hard-to-Reach Healthcare Professionals: Engage In On-line Communities
Prescribers, pharmacists, and medical directors all have an ongoing need for information on the latest advances in their respective fields. Yet, it is increasingly difficult for life sciences to deliver product information via in-person rep visits; in fact, many busy professionals have a policy a...
By Dr. Theodore Search • Jan. 1, 2016 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
As we look forward to 2016, there are any number of trends that will impact the life-sciences industry from molecule to market. For our special Year in Preview issue, we have compiled insights from more than 120 industry experts — who represent all areas of the industry — on 10 trends that we be...
By Taren Grom • Nov. 15, 2015 -
PharmaVoice Team/PharmaVoice
UpFront
Industry at Large Novartis Launches Novartis Access in Lower-Income Countries Novartis has launched Novartis Access, a portfolio of 15 medicines to treat chronic diseases in low- and low-middle-income countries. The portfolio addresses cardiovascular diseases, diabetes, respiratory illnesses, an...
By PharmaVoice Team • Nov. 15, 2015
Previous
